Arvinas to Present at the UBS Global Healthcare Virtual Conference
May 20 2021 - 4:30PM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that John Houston, Ph.D., President
and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific
Officer, will participate in a fireside chat at the UBS Global
Healthcare Virtual Conference on Tuesday, May 25 at 10:00 a.m. ET.
A live audio webcast of the presentation will be available here
and on Arvinas’ website at www.arvinas.com. A replay of the webcast
will be archived on Arvinas’ website for 30 days following the
presentation.
About ArvinasArvinas is a clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients suffering from debilitating and life-threatening diseases
through the discovery, development, and commercialization of
therapies that degrade disease-causing proteins. Arvinas uses its
proprietary PROTAC® Discovery Engine platform to engineer
proteolysis targeting chimeras, or PROTAC® targeted protein
degraders, that are designed to harness the body’s own natural
protein disposal system to selectively and efficiently degrade and
remove disease-causing proteins. In addition to its robust
preclinical pipeline of PROTAC® protein degraders against validated
and “undruggable” targets, the company has two clinical-stage
programs: ARV-110 for the treatment of men with metastatic
castrate-resistant prostate cancer; and ARV-471 for the treatment
of patients with locally advanced or metastatic ER+/HER2- breast
cancer. For more information, visit www.arvinas.com.
Contacts for Arvinas
InvestorsWill O’Connor, Stern Investor
Relations ir@arvinas.com
MediaKirsten Owens, Arvinas
Communicationskirsten.owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Apr 2024 to May 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From May 2023 to May 2024